骨转移瘤患者^(89)SrCl_2治疗后TNF-α、IL-2水平的变化  

The changes of TNF-α and IL-2 after the treatment of ^(89)SrCl_2 in the patients with bone metastases

作　　者：房娜[1] 李勇[1] 杨志杰[1] 

机构地区：[1]哈尔滨医科大学第一临床医学院核医学科,黑龙江哈尔滨150001

出　　处：《中国老年学杂志》2004年第7期579-580,共2页Chinese Journal of Gerontology

基　　金：黑龙江省十五攻关课题 (GC0 2C1 4 7 0 1 )

摘　　要：目的　观察骨转移瘤患者经89SrCl2 治疗前后TNF α、IL 2的变化及二者与患者预后的关系。方法　选择经临床确诊的应用89SrCl2治疗的患者 33例及正常对照组 1 7例。分别测定各患者治疗前后及正常对照组TNF α、IL 2值 ,并比较死亡患者与存活患者各免疫学指标。结果　正常对照组TNF α、IL 2分别为 1 1 4± 0 40、5 0± 1 5 ;骨转移瘤患者治疗前为 1 93± 0 35、2 55± 0 68,治疗后为 1 1 2± 0 1 2、3 53± 1 0 1。骨转移瘤患者治疗前后各免疫学指标均有显著差异 (P <0 0 5)。 1年内死亡 1 4例 ,其TNF α高于存活患者 ,IL 2低于存活患者 ,各指标间差异有统计学意义 (P <0 0 5)。结论　TNF α、IL 2是反映骨转移瘤治疗效果、判断预后的灵敏指标。Objective To explore the influence of 89 SrCl 2 on TNF α, IL 2 in the patients with bone metastases and study the relativities between the indexes and prognosis of the patients Methods The TNF, IL 2 were detected before and after 89 SrCl 2 treatment in 33 patients diagnosed by clinic and 17 controls The difference of the immune indexes between the survivals and the death patients was also compared Results The levels of TNF α, IL 2 in the control group were 1 14±0 40, 5 0±1 5 The results of the index of the patients with bone metastases before the therapy were 1 93±0 35, 2 55±0 68 and after the therapy were 1 1±0 12, 3 53±1 01, respectively The indexes between the patients and controls, before and after the therapy, were all have significant difference ( P <0 05) 14 patients died in a year after therapy and their TNF α levels were higher and IL 2 levels were lower than the survivals' The differences were significant too ( P <0 05) Conclusions TNF-αand IL-2 were sensitive indexes to reflect the therapeutic effect of 89 SrCl 2 and predict the prognosis of the patients

关 键 词：骨转移瘤 TNF-A IL-2 ^89SRCL2 

分 类 号：R817.9[医药卫生—影像医学与核医学]